{"entity":"amgen","id":"ent_amgen","name":"Amgen","wikidata":"Q470517","page":"https://asof.is/record/amgen","summary":"Amgen is an American multinational biopharmaceutical company, headquartered in Thousand Oaks. It reported revenue of $33.42B for the period ended December 31, 2024.","title":"Amgen: revenue $33.42B","key_facts":[{"label":"Chair","value":"Robert A. Bradway","claim":"clm_3662BB7CA128"},{"label":"Headquarters","value":"Thousand Oaks","claim":"clm_213F34219223"},{"label":"Revenue","value":"$33.42B","recorded":"33,424,000,000 United States dollar","note":"to 2024-12-31","claim":"clm_F31DA2CA4F3F"},{"label":"Ticker","value":"AMGN · Nasdaq","claim":"clm_3FB6D299561D"}],"faq":[{"question":"Where is Amgen headquartered?","answer":"Thousand Oaks."},{"question":"What is Amgen's revenue?","answer":"$33.42B for the period ended December 31, 2024."}],"as_of":"2025-11-08","known_by":null,"since":null,"fact_pages":[{"predicate":"chair","page":"https://asof.is/record/amgen/chair","md":"https://asof.is/record/amgen/chair.md","json":"https://asof.is/v1/entities/amgen/chair"},{"predicate":"headquarters","page":"https://asof.is/record/amgen/headquarters","md":"https://asof.is/record/amgen/headquarters.md","json":"https://asof.is/v1/entities/amgen/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/amgen/revenue","md":"https://asof.is/record/amgen/revenue.md","json":"https://asof.is/v1/entities/amgen/revenue"},{"predicate":"net_income","page":"https://asof.is/record/amgen/net_income","md":"https://asof.is/record/amgen/net_income.md","json":"https://asof.is/v1/entities/amgen/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/amgen/operating_income","md":"https://asof.is/record/amgen/operating_income.md","json":"https://asof.is/v1/entities/amgen/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/amgen/quarterly_revenue","md":"https://asof.is/record/amgen/quarterly_revenue.md","json":"https://asof.is/v1/entities/amgen/quarterly_revenue"}],"products":[],"coverage":{"entity":"amgen","name":"Amgen","kind":"organization","sources":[{"source":"wikidata","item":"Q470517","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":318154,"ticker":"AMGN","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":525,"open":20,"retracted":0,"first":"1980-01-01","predicates":{"quarterly_operating_income":{"claims":56,"open":1,"kind":"fact"},"operating_income":{"claims":19,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":56,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":76,"open":1,"kind":"fact"},"shares_outstanding":{"claims":70,"open":1,"kind":"fact"},"net_income":{"claims":19,"open":1,"kind":"fact"},"total_equity":{"claims":73,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":56,"open":1,"kind":"fact"},"total_assets":{"claims":71,"open":1,"kind":"fact"},"revenue":{"claims":19,"open":1,"kind":"fact"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"x_username":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"website":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"cik":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":523,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":2,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_8E5607E4B59B","predicate":"cash_and_equivalents","value":"9,445,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,445,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_8E5607E4B59B, https://asof.is/claim/clm_8E5607E4B59B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_8E5607E4B59B","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F9355A194FAC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_3662BB7CA128","predicate":"chair","value":"Robert A. Bradway","valid_from":"2013-01-01","valid_to":null,"published":"2026-04-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen chair: Robert A. Bradway\", as of 2013-01-01. Claim clm_3662BB7CA128, https://asof.is/claim/clm_3662BB7CA128, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312526145588/d13946ddef14a.htm.","url":"https://asof.is/claim/clm_3662BB7CA128","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000119312526145588/d13946ddef14a.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-04-07T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"Robert A. Bradway has served as our director since 2011 and Chairman of the Board since 2013.","url":"https://www.sec.gov/Archives/edgar/data/318154/000119312526145588/d13946ddef14a.htm"}},{"id":"clm_F44BD9859244","predicate":"cik","value":"0000318154","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cik: 0000318154\", undated. Claim clm_F44BD9859244, https://asof.is/claim/clm_F44BD9859244, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_F44BD9859244","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_932BE2EE8880","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen fiscal year end: 12-31\", undated. Claim clm_932BE2EE8880, https://asof.is/claim/clm_932BE2EE8880, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_932BE2EE8880","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_213F34219223","predicate":"headquarters","value":"Thousand Oaks","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen headquarters: Thousand Oaks\", undated. Claim clm_213F34219223, https://asof.is/claim/clm_213F34219223, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_213F34219223","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_4091015E92FD","predicate":"listed_on","value":"Nasdaq","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen listed on: Nasdaq\", undated. Claim clm_4091015E92FD, https://asof.is/claim/clm_4091015E92FD, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_4091015E92FD","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_ED179BBDEBC9","predicate":"net_income","value":"4,090,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 4,090,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_ED179BBDEBC9, https://asof.is/claim/clm_ED179BBDEBC9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_ED179BBDEBC9","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_70EECF48CD48","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-14"}},{"id":"clm_14D79C128253","predicate":"operating_income","value":"7,258,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 7,258,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_14D79C128253, https://asof.is/claim/clm_14D79C128253, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_14D79C128253","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_92AC0DE5846F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-14"}},{"id":"clm_E7FF81925833","predicate":"quarterly_net_income","value":"3,216,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 3,216,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_E7FF81925833, https://asof.is/claim/clm_E7FF81925833, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_E7FF81925833","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B9855476A1FF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_A957F605C563","predicate":"quarterly_operating_income","value":"2,526,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,526,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_A957F605C563, https://asof.is/claim/clm_A957F605C563, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_A957F605C563","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8FA61AE28EA3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_56EFD8BFD444","predicate":"quarterly_revenue","value":"9,557,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 9,557,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_56EFD8BFD444, https://asof.is/claim/clm_56EFD8BFD444, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_56EFD8BFD444","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BA3B03AF2A85","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_7924DEE14027","predicate":"registrant_name","value":"AMGEN INC","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen registrant name: AMGEN INC\", undated. Claim clm_7924DEE14027, https://asof.is/claim/clm_7924DEE14027, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_7924DEE14027","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_F31DA2CA4F3F","predicate":"revenue","value":"33,424,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 33,424,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_F31DA2CA4F3F, https://asof.is/claim/clm_F31DA2CA4F3F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_F31DA2CA4F3F","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3DD4895A6205","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-14"}},{"id":"clm_2EA05ED8BE57","predicate":"shares_outstanding","value":"538,480,671 shares","valid_from":"2025-10-30","valid_to":"2026-02-10","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 538,480,671 shares\", as of 2025-10-30 (until 2026-02-10). Claim clm_2EA05ED8BE57, https://asof.is/claim/clm_2EA05ED8BE57, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_2EA05ED8BE57","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_231B73F793B2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_EDF8DD683D0B","predicate":"sic_industry","value":"Biological Products, (No Diagnostic Substances) (2836)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen sic industry: Biological Products, (No Diagnostic Substances) (2836)\", undated. Claim clm_EDF8DD683D0B, https://asof.is/claim/clm_EDF8DD683D0B, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_EDF8DD683D0B","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_56FF368E6750","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen state of incorporation: DE\", undated. Claim clm_56FF368E6750, https://asof.is/claim/clm_56FF368E6750, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_56FF368E6750","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_3FB6D299561D","predicate":"ticker","value":"AMGN","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen ticker: AMGN\", undated. Claim clm_3FB6D299561D, https://asof.is/claim/clm_3FB6D299561D, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_3FB6D299561D","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_A3A1C9D984F8","predicate":"total_assets","value":"90,141,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 90,141,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_A3A1C9D984F8, https://asof.is/claim/clm_A3A1C9D984F8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_A3A1C9D984F8","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D061D89A7312","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_25EEFB9574DF","predicate":"total_equity","value":"9,619,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 9,619,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_25EEFB9574DF, https://asof.is/claim/clm_25EEFB9574DF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_25EEFB9574DF","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DEE8552AC913","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_DDCF286895FD","predicate":"website","value":"http://www.amgen.com/","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen website: http://www.amgen.com/\", undated. Claim clm_DDCF286895FD, https://asof.is/claim/clm_DDCF286895FD, accessed 2026-11-09. Source: https://www.wikidata.org/wiki/Q470517.","url":"https://asof.is/claim/clm_DDCF286895FD","accessed":"2026-11-09"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q470517","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"Amgen | A Worldwide Pioneer in Biotechnology.","url":"https://www.amgen.com/"}},{"id":"clm_683636E2586E","predicate":"x_username","value":"Amgen","valid_from":"2009-04-02","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen x username: Amgen\", as of 2009-04-02. Claim clm_683636E2586E, https://asof.is/claim/clm_683636E2586E, accessed 2026-11-09. Source: https://www.wikidata.org/wiki/Q470517.","url":"https://asof.is/claim/clm_683636E2586E","accessed":"2026-11-09"},"confidence":0.6,"status":"unverified","assertable":false,"why_not":"unverified","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q470517","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"http://www.twitter.com/amgen","url":"http://www.amgen.com/"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"sec-filing":"parsed from the SEC filing","page-read":"its source page states the value and the date","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}